Abstracts tagged "Health Assessment Questionnaire"

Abstract Number: 583 • 2014 ACR/ARHP Annual Meeting
What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction
Proton Rahman¹, Michel Zummer², Wojciech Olszynski³, Majed Khraishi⁴, Dalton Sholter⁵, Rafat Faraawi⁶, William Bensen⁷, Milton Baker⁸, Andrew Chow⁹, Julie Vaillancourt¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J Lehman¹², Susan Otawa¹² and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Université de Montréal, Montreal, QC, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵University of Alberta, Edmonton, AB, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose Despite the importance of the Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in assessing patient-reported functional status and disease…
Abstract Number: 552 • 2014 ACR/ARHP Annual Meeting
Sustained Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Non-Radiographic Axial Spondyloarthritis
Désirée van der Heijde¹, Manish Mittal², Naijun Chen², Aileen L. Pangan² and Avani D. Joshi², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL
Background/Purpose: In the ABILITY-1 trial, adalimumab (ADA) treatment for 12 weeks was associated with improved clinical and health-related quality of life (HRQOL) outcomes among patients…
Abstract Number: 430 • 2014 ACR/ARHP Annual Meeting
Minimally Important Difference in the European Quality of Life-Five Dimensions in Patients with Rheumatoid Arthritis
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Kumi Shidara, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Patient-reported outcomes (PROs) have been recognized as important in evaluating disease status of rheumatoid arthritis (RA). The minimally important difference (MID) in PROs has…
Abstract Number: 417 • 2014 ACR/ARHP Annual Meeting
Normal Scores of “0” (floor effects) Are Seen in 33-83% of Patients with Rheumatoid Arthritis (RA) on 8 HAQ Activities Which Also Are Found on the MDHAQ, but in Fewer Than 32% of Patients on 2 Unique MDHAQ Complex Activities “Walk 2 Miles or 3 Kilometers,” and “Participate in Recreation and Sports.”
Isabel Castrejón¹, Martin J. Bergman², Kathryn A. Gibson³, John Meyerhoff⁴ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Taylor Hospital, Ridley Park, PA, ³Liverpool Hospital, Liverpool, Australia, ⁴Sinai Hospital, Baltimore, MD
Background/Purpose: Patients with rheumatoid arthritis (RA) have significantly better clinical status in recent years compared with previous decades.1 Health assessment questionnaire (HAQ) scores were almost…
Abstract Number: 2860 • 2014 ACR/ARHP Annual Meeting
Randomised Comparison of the Effectiveness of a Non-Pharmacological Multidisciplinary Face-to-Face Group-Based Treatment Program Vs. a Telephone-Delivered Treatment Program on Daily Function in Patients with Generalized Osteoarthritis
Nienke Cuperus¹, Thomas Hoogeboom², Clarinda Kersten³, Leonie Rietveld⁴, Alfons den Broeder⁴, Thea Vliet Vlieland⁵ and Cornelia H.M. van den Ende⁴, ¹Rheumatology Department, Sint Maartenskliniek, Nijmegen, Netherlands, ²Department of Epidemiology, CAPHRI school for public health and primary care, CCTR centre for Care Technology Research, Maastricht University, Maastricht, Netherlands, ³Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Dept of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Generalized osteoarthritis (GOA) is a widely accepted and prevalent OA phenotype characterized by the involvement of multiple joints. However, current research and clinical practice…
Abstract Number: 390 • 2014 ACR/ARHP Annual Meeting
Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis
John M. Davis III¹, Cynthia S. Crowson², Tim Bongartz¹, Clement J. Michet¹, Eric L. Matteson¹ and Sherine E. Gabriel³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) sometimes rate their global disease activity differently than their rheumatologists. Previous studies describing this ‘discordance’ have primarily included patients…
Abstract Number: 2488 • 2014 ACR/ARHP Annual Meeting
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
Roy Fleischmann¹, V Strand², B Wilkinson³, K Kwok⁴ and E Bananis³, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, ²Biopharmaceutical Consultant, Portola Valley, CA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the relationship between clinical measures and patient-reported…
Abstract Number: 226 • 2014 ACR/ARHP Annual Meeting
Improved Prediction of Hip Fracture Using the Health Assessment Questionnaire-Disability Index and FRAX^® in Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Study
Takefumi Furuya¹, Eisuke Inoue², Kensuke Ochi¹, Osamu Ishida³, Atsuo Taniguchi⁴, Shigeki Momohara⁴ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopedics, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: The World Health Organization Fracture Risk Assessment Tool (FRAX®) algorithm can be used to estimate 10-year probabilities of hip and major osteoporotic fractures. Previously,…
Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
V. Strand¹, R. Riese², R. Gerber², D. Gruben², A.G. Bushmakin², E.Y. Mahgoub³ and G. Wallenstein², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
Abstract Number: 2394 • 2014 ACR/ARHP Annual Meeting
Sustained Remission Improves Physical Function in RA Patients Treated with Tumor Necrosis Factor Inhibitor
Jon T. Einarsson¹, Meliha C. Kapetanovic² and Pierre Geborek³, ¹Dept of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ³Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Sustained Remission Improves Physical Function In RA Patients Treated with Tumor Necrosis Factor InhibitorsBackground/Purpose Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA)…
Abstract Number: 2386 • 2014 ACR/ARHP Annual Meeting
Patients’ Interpretations of Rheumatoid Arthritis Model Disease States in a Safety-Net Rheumatology Clinic
Carol Bledsoe¹, Lisa A. Davis², Vivian Tran³, Angela Keniston⁴, Liron Caplan⁵, Itziar Quinzanos⁶ and Joel M. Hirsh³, ¹The Brody School of Medicine - East Carolina University, Greenville, NC, ²Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ³Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁴Department of Medicine, Denver Health and Hospital Authority, Denver, CO, ⁵Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ⁶Department of Medicine, Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Patient assessment of disease activity (PtGA) measured by visual analog scale (VAS) is often a barrier to patients achieving remission in rheumatoid arthritis (RA).…
Abstract Number: 2329 • 2014 ACR/ARHP Annual Meeting
Course and Outcome of Rehabilitation Care in Different Rheumatological Diagnosis Groups. a Descriptive Study Using the STAR-Etic Registry
Elisabet Lindqvist¹, Margreth Grotle², Kim Hoerslev-Petersen³, Theodora P.M. Vliet Vlieland⁴ and Ann B. I. Bremander⁵, ¹Department of Clinical Sciences, Lund, Section for Rheumatology, Lund, Lund University and Skåne University Hospital, Lund, Sweden, ²Rheumatology, National Resource Centre for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway, ³Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁴Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands, ⁵Spenshult Research and Development Center, Halmstad, Sweden
Background/Purpose: The frequency of admission to rehabilitation varies among countries but also among diagnosis groups. So far research describing and comparing the rehabilitation in various…
Abstract Number: 2054 • 2014 ACR/ARHP Annual Meeting
Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-Year Follow-up Period: The Role of Specific Comorbidities
Joëlle van den Hoek¹, Leo D. Roorda², Hendriek C. Boshuizen³, Gerard J. Tijhuis⁴, Trudi van den Bos⁵ and Joost Dekker⁶, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Comorbidity in patients with Rheumatoid Arthritis (RA) is highly prevalent and plays an important role in determining RA related outcomes. Several studies have reported…
Abstract Number: 2028 • 2014 ACR/ARHP Annual Meeting
Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort
Thomas Krams¹, Adeline Ruyssen-Witrand², Delphine Nigon¹, Bruno Fautrel^3,4,5, Francis Berenbaum^6,7, Alain G. Cantagrel⁸ and Arnaud Constantin⁹, ¹Rhumatologie, Purpan University Hospital, Toulouse, France, ²Rheumatology, Purpan University Hospital, Toulouse, France, ³Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁴Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁵Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁶Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, ⁷INSERM - UMR S 938, Paris, France, ⁸Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁹Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease with peak incidence in the fourth and fifth decades of age. To investigate whether age at disease…
Abstract Number: 1551 • 2014 ACR/ARHP Annual Meeting
Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction
Denis Choquette¹, Carter Thorne², Majed Khraishi³, Isabelle Fortin⁴, Regan Arendse⁵, Andrew Chow⁶, John Kelsall⁷, Milton Baker⁸, Julie Vaillancourt⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹ and May Shawi¹⁰, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁷The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The Health Assessment Questionnaire (HAQ) is commonly used for assessing patient-reported functional status and disease activity in psoriatic arthritis (PsA). However, it has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].